Building a Biotech Pipeline Without a Lab | Nona Biosciences

Venture-backed biotechs routinely advance programs from concept to clinical candidate without owning a single piece of lab equipment. Outsourcing antibody discovery is now a standard operating model, but the decisions made at the outset – which platform, which partner, which IP structure – determine whether a program reaches IND on schedule or stalls in renegotiation.

The questions below address the most common decision points for founders, CSOs, and VPs of R&D navigating this process.

What does “outsourcing antibody discovery” actually mean for a biotech with no internal lab?

Outsourcing antibody discovery means contracting a specialized partner to execute every wet-lab step a biotech cannot perform internally, from antigen preparation and animal immunization through screening, lead generation, engineering, and developability assessment. For a capital-efficient startup, this model replaces the need for animal facilities, high-throughput screening infrastructure, and the specialized scientific staff required to operate them. The partner delivers characterized antibody leads, sequence data, and supporting assay packages that the biotech team can evaluate and advance.

The scope of outsourcing varies. Some biotechs hand off a single campaign and retain internal engineering capacity; others contract an end-to-end pathway. Nona Biosciences offers an integrated end-to-end service pathway from ideation through IND filing, structured specifically for the latter scenario, covering target validation, discovery, preclinical research, and IND-enabling studies under a single integrated framework.

What are the non-negotiable contract terms every VC-backed biotech should secure before signing with a discovery partner?

Full IP ownership of all discovered sequences and constructs is the single most critical term for any VC-backed biotech. Royalty obligations and late-stage commercial milestones attached to discovered antibodies can materially impair a company’s ability to raise follow-on financing or execute an acquisition exit, because acquirers and investors price these encumbrances into valuations.

Freedom to Operate (FTO) is equally non-negotiable. A partner that cannot provide clean FTO on the antibody sequences it generates creates downstream licensing risk that can block clinical development entirely. Nona Biosciences grants clients full IP ownership of discovered antibodies and operates on a fee-for-service model with a one-time successful IND filing milestone, rather than stacking royalties or heavy upfront payments. Legal teams should review Master Service Agreements carefully for any language that reserves rights to sequences, screening data, or platform-derived improvements.

Which antibody format should a biotech without internal engineering capacity prioritize?

Fully human heavy-chain-only antibodies (HCAbs) offer the most engineering flexibility for biotechs that lack internal antibody engineering teams, particularly for programs targeting bispecific, multispecific, or T-cell engager formats. Because HCAbs consist of a single heavy chain without a light chain, they eliminate the chain mispairing problem that complicates conventional bispecific manufacturing: when two different heavy chains and two different light chains are co-expressed, the light chains can pair with the wrong heavy chain, generating non-functional or heterogeneous product. HCAb-derived single domains sidestep this problem entirely, enabling cleaner assembly of complex constructs.

Conventional IgG formats remain appropriate for programs where a standard bivalent mechanism of action is sufficient and bispecific engineering is not anticipated. The table below summarizes the key format considerations:

Nona Biosciences’ fully human antibody discovery service covers both HCAb and H2L2 formats through Harbour Mice® (transgenic mice engineered to produce fully human heavy-chain-only antibodies), giving programs the option to run parallel campaigns and compare format performance before committing to a lead series.

Is a fully human antibody the same as a humanized antibody?

Fully human and humanized antibodies are produced through fundamentally different processes and carry different immunogenicity profiles. A fully human antibody is derived entirely from human gene sequences, produced in vivo through natural immune selection in a transgenic system such as Harbour Mice®. A humanized antibody starts as a non-human sequence, typically murine, and is then engineered to replace non-human framework regions with human equivalents while retaining the original binding loops.

The practical consequence is that humanized antibodies retain residual non-human residues that can trigger anti-drug antibody responses in patients, a risk that is absent in fully human sequences. For VC-backed biotechs building programs intended for clinical development, this distinction affects both regulatory strategy and long-term safety profiling. Fully human sequences derived from Harbour Mice® are inherently compatible with human immune tolerance because they are generated using human VH gene segments from the outset, not engineered after the fact.

Is an HCAb the same as a VHH nanobody from a camelid?

HCAbs from Harbour Mice® and camelid-derived VHH nanobodies are structurally related but scientifically and clinically distinct. Both are single-domain antibody formats that lack a light chain, but camelid VHH sequences are derived from llama or camel immune repertoires and require humanization before clinical use, introducing the same residual non-human residue risk described above. Prospects sometimes treat these formats as interchangeable, but the immunogenicity implications are materially different.

Fully human HCAbs produced by Harbour Mice® use human VH gene segments selected for developability, generating binders that are fully human from the point of immune selection. No post-hoc humanization step is required, and no non-human residues are introduced. This distinction is particularly relevant for programs in autoimmune or neurological indications, where chronic dosing makes immunogenicity risk a more significant clinical concern.

How long does an outsourced antibody discovery campaign realistically take, and what drives timeline variation?

A complete outsourced antibody discovery campaign, from immunization through delivery of characterized leads, can span several months under conventional hybridoma-based workflows. Nona Biosciences advocates for a two-month immunization protocol to ensure high-quality immune responses and adequate titer development, rather than compressing immunization to three weeks at the cost of unknown antibody quality. Screening timelines are then compressed using single B-cell (SBC) cloning, which takes approximately one month compared to two to three months for traditional hybridoma fusion.

The primary drivers of timeline variation are target difficulty, antigen quality, and the screening platform used. Difficult targets, including membrane proteins, highly conserved antigens, and targets requiring functional selectivity, routinely extend campaigns. The Beacon® (single B-cell screening instrument used for high-recovery HCAb isolation) enables high-throughput single B-cell screening that recovers a broader diversity of binders per campaign, reducing the likelihood of needing to repeat immunization rounds due to insufficient hit diversity.

What decision-making process should VC-backed biotechs follow before engaging a discovery partner?

For VC-backed biotechs operating with limited internal laboratory infrastructure, selecting a discovery partner is often one of the most consequential early R&D decisions. Before initiating a program, leadership teams should ensure alignment around three core questions: whether the partner can support the scientific objectives, whether the engagement fits the company’s development strategy and budget, and whether the expected outcomes justify the investment.
In many organizations, scientific leadership evaluates whether a partner’s capabilities align with the biology, target class, and therapeutic objectives of the program. At the same time, executive leadership assesses timeline expectations, resource requirements, and overall fit within broader corporate priorities. Early consideration of intellectual property, technology access, and future development flexibility is also important.

Rather than focusing solely on vendor comparisons, companies benefit from defining program goals upfront. A clear target rationale, desired molecule characteristics, anticipated development path, and key success criteria can help ensure productive discussions and accelerate decision-making. This preparation enables management teams and investors to evaluate opportunities against strategic objectives and make informed outsourcing decisions with greater confidence.

When should a biotech consider Nona’s AI-assisted lead selection rather than relying solely on in vivo screening output?

AI-assisted lead selection adds the most value when a campaign generates a large number of binders and the team needs to prioritize candidates for downstream engineering without the resources to run every hit through full developability panels. Nona Biosciences’ Hu-mAtrIx™ (Nona’s AI platform for antibody lead selection and developability optimization) is integrated into the discovery workflow to guide selection of sequences with favorable developability profiles, reducing the risk of advancing leads that will fail later due to aggregation, poor expression, or stability issues.

For biotechs without internal computational biology capacity, this integration is particularly valuable because developability failures at the lead optimization stage are expensive to recover from and can delay IND timelines by months. Hu-mAtrIx™ extends the value of Harbour Mice® HCAb campaigns by incorporating developability-optimized sequence guidance into the selection process, rather than treating developability as a separate downstream filter. Teams can learn more about how this platform operates on Nona’s Hu-mAtrIx™ technology page.

What clinical validation exists for antibodies discovered through Nona’s platforms?

Nona Biosciences has an established track record across multiple therapeutic areas, with oncology accounting for the largest share of programs, consistent with its position as the dominant therapeutic area by industry spending. Nona has documented partnerships with major pharmaceutical companies, including Pfizer, providing evidence that its platforms have been validated by large-scale industry collaborators.

For VC-backed biotechs conducting due diligence, the existence of pharma partnerships is a meaningful signal: it indicates that antibodies generated through Nona’s platforms have cleared the developability, manufacturing, and regulatory hurdles required to advance through drug development. Partnering with Nona provides access to a discovery infrastructure that has been stress-tested across diverse targets and modalities, including ADCs, bispecifics, and T-cell engagers, rather than relying on a platform with only preclinical proof points.

What should a biotech ask a discovery partner about its screening platform before committing to a campaign?

Four questions reveal the most about a screening platform’s fit for a specific program. First, what is the recovery rate for rare binders against difficult targets, and what instrument or method supports that claim? Second, does the platform support functional screening, or does it rely solely on binding affinity as a selection criterion? Third, how is antibody diversity maintained across the screened population, and what VH gene coverage does the platform provide? Fourth, what developability data is generated at the screening stage, and how early in the workflow are aggregation-prone or low-expression sequences deprioritized?

Nona’s Beacon® single B-cell screening platform addresses the recovery question directly, enabling high-throughput isolation of individual B cells with minimal loss of rare binders. NonaCarFx™ (Nona’s CAR-based functional screening platform) extends screening beyond binding affinity to assess functional activity, which is particularly relevant for T-cell engager and CAR-T programs where binding alone does not predict therapeutic efficacy. Biotechs evaluating partners should request platform-specific data, not just general capability claims, before committing campaign budgets.

Biotechs building pipelines without internal labs should evaluate discovery partners on IP structure, platform clinical validation, and the depth of integrated services available from a single contract.

To discuss how Nona Biosciences’ end-to-end Idea-to-IND pathway can be structured around a specific program’s target class, timeline, and format requirements, reach out to Nona’s scientific team directly.

1. Kaplon H. et al., Antibodies to watch in 2024, mAbs, 2024. Link

2. Labrijn A.F. et al., Bispecific antibodies: a mechanistic review of the pipeline, Nature Reviews Drug Discovery, 2019. Link

3. Tiller T. et al., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning, Journal of Immunological Methods, 2008. Link

4. Muyldermans S., A guide to: generation and design of nanobodies, FEBS Journal, 2021. Link

5. Xu Y. et al., Developability screening of antibody leads using high-throughput biophysical methods, mAbs, 2020. Link

6. Spiess C. et al., Alternative molecular formats and therapeutic applications for bispecific antibodies, Molecular Immunology, 2015. Link